참고문헌 (49)

1. Korean Society for the Study of Obesity. Clinical practice guidelines？for obesity, 8th edition. 2022:1-17. 

2. Korean Society for the Study of Obesity. 2021 obesity fact sheet.？Available from https://www.kosso.or.kr/file/2021_Obesity_Fact_Sheet_web_kor.pdf?v2307210355. Accessed July 21, 2023. 

3. Korean Diabetes Association. Clinical practice guidelines for diabetes. 2023:21-183. 

4. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type？2 diabetes. Lancet. 2006;368(9548):1696-705. 

5. Holst JJ. Glucagonlike peptide 1: a newly discovered gastrointestinal？hormone. Gastroenterology 1994;107(6):1848-55. 

6. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like？peptide 1 in type 2 diabetic patients. Diabetes 2001;50(3):609-13. 

   상세보기

7. Clarke T. FDA approves Novo Nordisk diabetes drug Ozempic. Reuters. 2017. Available from https://www.reuters.com/article/idUSKBN1DZ2O8/. Accessed December 18, 2023. 

8. U.S. Food and Drug Administration. FDA approves new drug treatment for chronic weight management, first since 2014. 2021. Available from https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-managementfirst-2014. Accessed December 18, 2023. 

9. Ministry of Food and Drug Safety. Ozempic prefilled pen (semaglutide). Available from https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetailCache?cacheSeq202201737aupdateTs2023-07-03%2017:55:00.0b. Accessed December 18, 2023. 

10. Ministry of Food and Drug Safety. Wegovy prefilled pen (semaglutide). Available from https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetailCache?cacheSeq202301387aupdateTs2023-12-15%2013:45:40.397763b. Accessed December 18, 2023. 

11. U.S. Food and Drug Administration. FDA approves first oral GLP-1？treatment for type 2 diabetes. 2019. Available from https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-glp-1-treatment-type-2-diabetes. Accessed December 18, 2023. 

12. Ministry of Food and Drug Safety. Rybelsus (semaglutide). Available from https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetailCache?cacheSeq202201785aupdateTs2023-11-09%2011:24:14.969223b. Accessed December 18, 2023. 

13. Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of？once-weekly semaglutide monotherapy versus placebo in patients？with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a？trial. Lancet Diabetes Endocrinol 2017;5(4):251-60. 

14. Rodbard HW, Lingvay I, Reed J, et al. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled？Trial. J Clin Endocrinol Metab 2018;103(6):2291-301. 

    상세보기

15. Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as？add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9):？a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol？2019;7(5):356-67. 

16. Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety？of once-weekly semaglutide versus exenatide ER in subjects with？type 2 diabetes (SUSTAIN 3): A 56-week, open-label, randomized？clinical trial. Diabetes Care 2018;41(2):258-66. 

    상세보기

17. Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a？randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol？2018;6(4):275-86. 

18. Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of？once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as？add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes？(SUSTAIN 10). Diabetes Metab 2020;46(2):100-9. 

19. Lingvay I, Catarig AM, Frias JP, et al. Efficacy and safety of？once-weekly semaglutide versus daily canagliflozin as add-on to？metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes？Endocrinol 2019;7(11):834-44. 

    상세보기

20. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly？semaglutide in adults with overweight or obesity. N Engl J Med？2021;384(11):989-1002. 

21. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued？weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized？clinical trial. JAMA 2021;325(14):1414-25. 

    상세보기

22. Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous？semaglutide vs placebo as an adjunct to intensive behavioral therapy？on body weight in adults with overweight or obesity: The STEP 3？randomized clinical trial. JAMA 2021;325(14):1403-13. 

    상세보기

23. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of？semaglutide in adults with overweight or obesity: the STEP 5 trial.？Nat Med 2022;28(10):2083-91. 

    상세보기

24. Weghuber D, Barrett T, Barrientos-Perez M, et al. Once-weekly semaglutide in adolescents with obesity. N Engl J Med？2022;387(24):2245-57. 

25. Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults？with overweight or obesity without diabetes: The STEP 8 randomized clinical trial. JAMA 2022;327(2):138-50. 

    상세보기

26. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med？2021;385(6):503-15. 

27. McGowan BM, Houshmand-Oeregaard A, Laursen PN, Zeuthen？N, Baker-Knight J. Impact of BMI and comorbidities on efficacy of？once-weekly semaglutide: Post hoc analyses of the STEP 1 randomized trial. Obesity (Silver Spring) 2023;31(4):990-28. 

28. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and？cardiometabolic effects after withdrawal of semaglutide: The STEP 1？trial extension. Diabetes Obes Metab 2022;24(8):1553-64. 

    상세보기

29. Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes.？Diabetes Care 2019;42(9):1724-32. 

    상세보기

30. Mosenzon O, Blicher TM, Rosenlund S, et al. Efficacy and safety of？oral semaglutide in patients with type 2 diabetes and moderate renal？impairment (PIONEER 5): a placebo-controlled, randomised, phase？3a trial. Lancet Diabetes Endocrinol 2019;7(7):515-27. 

    상세보기

31. Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet 2019;394(10192):39-50. 

32. Rodbard HW, Rosenstock J, Canani LH, et al. Oral semaglutide？versus empagliflozin in patients with type 2 diabetes uncontrolled on？metformin: The PIONEER 2 trial. Diabetes Care 2019;42(12):2272-81. 

    상세보기

33. Yabe D, Nakamura J, Kaneto H, et al. Safety and efficacy of oral？semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled,？phase 3a trial. Lancet Diabetes Endocrinol 2020;8(5):392-406. 

    상세보기

34. Yamada Y, Katagiri H, Hamamoto Y, et al. Dose-response, efficacy,？and safety of oral semaglutide monotherapy in Japanese patients with？type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised,？controlled trial. Lancet Diabetes Endocrinol 2020;8(5):377-91. 

    상세보기

35. Zinman B, Aroda VR, Buse JB, et al. Efficacy, safety, and tolerability？of oral semaglutide versus placebo added to insulin with or without？metformin in patients with type 2 diabetes: The PIONEER 8 trial.？Diabetes Care 2019;42(12):2262-71. 

    상세보기

36. Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50 mg？taken once per day in adults with overweight or obesity (OASIS 1):？a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet？2023;402(10403):705-19. 

37. American Diabetes Association. Standards of care in diabetes - 2023. Diabetes Care 2023;46(Suppl. 1). 

38. Blonde L, Umpierrez GE, Reddy SS, et al. American Association of？Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan - 2022 update. Endocr Pract？2022;28(10):923-1049. 

39. Korean Diabetes Association. Clinical practice guidelines for diabetes, 7th edition. 2021:89. 

40. Korean Diabetes Association. Clinical practice guidelines for diabetes, 8th edition. 2023:125. 

41. Grunvald E, Shah R, Hernaez R, et al. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology 2022;163(5):1198-225. 

42. DrFirst. Ozempic this, Wegovy that: no matter what you call it,？semaglutide is having a moment. 2023. Available from https://drfirst.com/press-releases/ozempic-this-wegovy-that-no-matter-what-youcall-it-semaglutide-is-having-a-moment/. Accessed February 13, 2024. 

43. McPhillips D. CNN exclusive: prescriptions for popular diabetes？and weight-loss drugs soared, but access is limited for some patients.？CNN. 2023. Available from https://edition.cnn.com/2023/09/27/health/semaglutide-equitable-access/index.html. Accessed February？13, 2024. 

44. American Society of Health-System Pharmacists. Semaglutide injection. 2024. Available from https://www.ashp.org/drug-shortages/current-shortages/drug-shortage-detail.aspx?id813&loginreturnUrlSSOCheckOnly. Accessed February 13, 2024. 

45. Klein HE. An ongoing crisis: semaglutide shortage raises dual concerns for obesity and diabetes treatment. American Journal of Managed Care. 2023. Available from https://www.ajmc.com/view/an-ongoing-crisis-semaglutide-shortage-raises-dual-concerns-for-obesity-and-diabetes-treatment. Accessed February 13, 2024. 

46. Leitner DR, Fruhbeck G, Yumuk V, et al. Obesity and type 2 diabetes: two diseases with a need for combined treatment strategies -？EASO can lead the way. Obes Facts 2017;10(5):483-92. 

    상세보기

47. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide？and cardiovascular outcomes in obesity without diabetes. N Engl J？Med 2023;389(24):2221-32. 

    상세보기

48. Wegovy (semaglutide) [Package Insert] Novo Nordis; Bagsvaerd,？Denmark: 2022. 

49. Park ET. Finally, a survey?...Is misuse of 'obesity treatment' okay?？Medipana. 2023. Available from: https://www.medipana.com/article/view.php?news_idx317626. Accessed February 29, 2024.